Cyclacel Pharmaceuticals, Inc.
CYCC
$7.99
-$0.01-0.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -70.37% | 344.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -73.85% | 175.49% | |||
| Operating Income | 73.85% | -175.49% | |||
| Income Before Tax | -1,524.69% | 95.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,527.16% | 97.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,527.16% | 97.35% | |||
| EBIT | 73.85% | -175.49% | |||
| EBITDA | 73.85% | -175.56% | |||
| EPS Basic | -1,528.46% | 99.88% | |||
| Normalized Basic EPS | 74.19% | 87.94% | |||
| EPS Diluted | -1,528.46% | 99.88% | |||
| Normalized Diluted EPS | 74.19% | 87.94% | |||
| Average Basic Shares Outstanding | 1.39% | 2,143.90% | |||
| Average Diluted Shares Outstanding | 1.39% | 2,143.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||